<!DOCTYPE html>

<html class="theme-light" lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>
   Variant-Responsive Vaccine Effectiveness
  </title>
<link href="../assets/css/al-folio.css" rel="stylesheet"/>
<link href="../assets/css/custom.css" rel="stylesheet"/>
</head>
<body class="page">
<div class="page__inner">
<header class="project-hero">
<div class="wrapper project-hero__inner">
<a class="back-link" href="../index.html">
      ‚Üê Back to portfolio
     </a>
<h1 class="project-hero__title">
      Variant-Responsive Vaccine Effectiveness
     </h1>
<p class="project-hero__subtitle">
      Analyzed global survey data to assess COVID-19 vaccine protection as new variants (Delta, Omicron) emerged.
     </p>
<div class="project-hero__meta">
<p>
<strong>
        Role:
       </strong>
       Principal Data Scientist &amp; Collaborator
      </p>
<p>
<strong>
        Focus:
       </strong>
       Survey-Based VE Modeling, Global Health
      </p>
</div>
</div>
</header>
<main class="wrapper project-body">
<div class="project-body__grid"><div class="project-body__sidebar"><section class="project-section project-section--at-a-glance">
<h2>
        At a Glance
       </h2>
<ul>
<li>
         Analyzed global survey data to assess COVID-19 vaccine protection as new variants (Delta, Omicron) emerged.
        </li>
<li>
         Compared infection rates among vaccinated vs unvaccinated groups during major variant waves.
        </li>
<li>
         Provided real-world evidence of vaccine efficacy changes against variants, informing booster strategies.
        </li>
</ul>
</section><section class="project-section project-section--gallery" data-gallery-count="2">
<h2>
        Visual highlights
       </h2>
<div class="project-gallery"><figure class="project-gallery__item project-gallery__item--feature"><a href="10.1.covid-vaccine-effectiveness-against-mild-vs-severe-illness.png" rel="noopener" target="_blank">
<img alt="Vaccine effectiveness against mild versus severe illness" decoding="async" loading="lazy" src="10.1.covid-vaccine-effectiveness-against-mild-vs-severe-illness.png"/>
</a><figcaption>Vaccine effectiveness against mild versus severe illness</figcaption></figure>
<figure class="project-gallery__item">
<a href="10.2.covid-vaccine-effectiveness-change-from-delta-to-omnicron.png" rel="noopener" target="_blank">
<img alt="Change in vaccine effectiveness from Delta to Omicron" decoding="async" loading="lazy" src="10.2.covid-vaccine-effectiveness-change-from-delta-to-omnicron.png"/>
</a>
<figcaption>
          Variant comparison chart informed timing of booster recommendations.
         </figcaption>
</figure>
</div>
</section></div><div class="project-body__main"><section class="project-section">
<h2>
        The Problem
       </h2>
<ul>
<li>
         Emerging variants threatened to erode vaccine protection, creating need for real-time effectiveness data.
        </li>
<li>
         Traditional clinical studies lagged in measuring vaccine performance across diverse regions and variant strains.
        </li>
<li>
         Policymakers lacked timely insight on whether vaccines remained protective, risking delayed booster responses.
        </li>
</ul>
</section><section class="project-section">
<h2>
        The Solution
       </h2>
<ul>
<li>
         Leveraged a global Facebook user survey to gather self-reported vaccination status and COVID outcomes daily across 100+ countries.
        </li>
<li>
         Analyzed millions of responses to compare COVID-like illness rates in vaccinated vs unvaccinated populations over variant waves.
        </li>
<li>
         Used statistical models to estimate infection risk reduction by vaccine status for each variant, adjusting for demographics.
        </li>
</ul>
</section><section class="project-section">
<h2>
        Architecture Overview
       </h2>
<ul>
<li>
         Data Integration: Aggregated daily survey responses and aligned them with variant prevalence timelines from genomic surveillance.
        </li>
<li>
         Variant Segmentation: Tagged survey data by time and region to correlate infection rates with dominant variants (e.g. Delta, Omicron).
        </li>
<li>
         Effectiveness Modeling: Employed statistical and ML models to compute odds ratios of infection for vaccinated vs unvaccinated groups per variant.
        </li>
<li>
         Dashboard &amp; Visualization: Built a dashboard to visualize vaccine performance trends over time and across regions as variants arose.
        </li>
<li>
         Quality Control: Weighted survey data for representation and validated model outputs against external case and hospitalization data.
        </li>
</ul>
</section><section class="project-section">
<h2>
        Results and Impacts
       </h2>
<ul>
<li>
         Demonstrated high vaccine effectiveness (~85%) against early COVID strains, with moderate declines against Delta and further reduction against Omicron.
        </li>
<li>
         Real-time analysis flagged waning vaccine protection with new variants, supporting timely public health decisions on booster recommendations.
        </li>
<li>
         Showed that participatory survey data can rapidly evaluate vaccine performance globally, influencing policy in areas lacking formal studies.
        </li>
</ul>
</section><section class="project-section">
<h2>
        Skills and Tools Used
       </h2>
<div class="project-table-wrapper">
<table class="project-table">
<tr>
<th>
           Data Analysis
          </th>
<th>
           Large-scale survey data processing (Python, R)
          </th>
</tr>
<tr>
<td>
           Epidemiological Modeling
          </td>
<td>
           Vaccine effectiveness calculations (odds ratios, risk reduction)
          </td>
</tr>
<tr>
<td>
           Data Integration
          </td>
<td>
           Merged survey outcomes with variant prevalence data
          </td>
</tr>
<tr>
<td>
           Cloud &amp; Collaboration
          </td>
<td>
           Scalable cloud pipeline; coordinated analysis across institutions
          </td>
</tr>
</table>
</div>
</section><section class="project-section">
<h2>
        Cross-Project Capabilities
       </h2>
<ul>
<li>
         Rapid Public Health Analysis: Ability to quickly analyze global data for urgent health decisions (e.g., pandemic response).
        </li>
<li>
         Adaptive Modeling: Experience adjusting models for evolving conditions (new variants) transferable to other dynamic scenarios.
        </li>
<li>
         Global Survey Expertise: Strengthened skills in using large participatory datasets to complement traditional surveillance in various domains.
        </li>
</ul>
</section><section class="project-section">
<h2>
        Published Papers/Tools
       </h2>
<ul>
<li>
         Study results published in Nature Communications Medicine (2024), detailing vaccine efficacy trends across variants. <a class="paper-link" href="https://scholar.google.com/scholar?q=Nature+Communications+Medicine+COVID-19+vaccine+effectiveness+Facebook+survey" rel="noopener" target="_blank">Paper</a>
        </li>
<li>
         Findings shared with global health authorities, providing data-driven guidance for booster policies and pandemic planning.
        </li>
</ul>
</section></div></div>
</main>
<footer class="wrapper project-footer">
<a class="btn btn--ghost" href="../index.html">
     Back to portfolio
    </a>
</footer>
</div>
</body>
</html>
